EUVIMEDEUVIMED entdecken
EditorialHistorischer Beitrag

CML 25 Years Later — Poised for Another Breakthrough?

Elisabetta Abruzzese

New England Journal of Medicine · 2024

DOI: 10.1056/nejme2407913 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, 2024. Verfasst von Elisabetta Abruzzese. Beteiligte Einrichtung: From the Department of Hematology, S. Eugenio Hospital, Tor Vergata University, Azienda Sanitaria Locale Roma 2, Rome. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 1960, the discovery of the Philadelphia chromosome in patients with chronic myeloid leukemia (CML) opened the door to the development of insights on the role of genes in human cancers. This pivotal finding was followed by the identification of the 9;22 chromosomal translocation and the BCR::ABL1 fusion gene, encoding an active tyrosine kinase that drives the onset of CML. This discovery paved the way for developing tyrosine kinase inhibitors (TKIs) in the early 2000s, revolutionizing cancer treatment. 1 The first TKI, imatinib, introduced a molecular approach to diagnosing, treating, and monitoring cancers, which showed how specific genetic mutations and aberrant . . .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTyrosine Kinase InhibitorsHumansFusion Proteins, bcr-ablHistory, 20th CenturyHistory, 21st CenturyClinical Trials, Phase III as TopicImatinib MesylateNiacinamidePyrazolesRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

Antineoplastic AgentsFusion Proteins, bcr-ablTyrosine Kinase InhibitorsImatinib MesylateasciminibNiacinamidePyrazoles

Autor:innen und Institutionen

  • From the Department of Hematology, S. Eugenio Hospital, Tor Vergata University, Azienda Sanitaria Locale Roma 2, Rome.

Zitieren

APA

Abruzzese, E. (2024). CML 25 Years Later — Poised for Another Breakthrough?. New England Journal of Medicine. https://doi.org/10.1056/nejme2407913

Vancouver

Abruzzese E. CML 25 Years Later — Poised for Another Breakthrough?. New England Journal of Medicine. 2024. doi:10.1056/nejme2407913

BibTeX
@article{Abruzzese2024,
  author = {Abruzzese, Elisabetta},
  title = {CML 25 Years Later — Poised for Another Breakthrough?},
  journal = {New England Journal of Medicine},
  year = {2024},
  doi = {10.1056/nejme2407913}
}
Kostenlos starten →